A pharmaceutical composition comprising: (i) a double-stranded nucleic acid molecule and drug carrier comprising a mixture of a retinoid and a lipid, wherein the double-stranded nucleic acid molecule comprises the structure: 5' x -Z 3' (antisense strand) 3' Z'-(N') y -z" 5' (sense strand) wherein each of N and N' is a nucleotide which may be unmodified or modified, or an unconventional moiety; wherein each of x and (N') y is an oligonucleotide in which each consecutive N or N' is joined to the next N or N' by a covalent bond; wherein each of Z and Z' is independently present or absent, but if present independently includes 1-5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3'-terminus of the strand in which it is present; wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5'-terminus of (N') y; wherein each of x and y is independently an integer between 18 and 40; wherein the sequence of (N') y has complementary to the sequence of x; wherein x includes an antisense sequence to the mRNA coding sequence for human hsp47 exemplified by SEQ ID NO:1; and wherein the lipid comprises a lipid selected from the group consisting of and or (ii) a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and a drug carrier comprising a mixture of a lipid vesicle and a retinoid or a retinoid conjugate, wherein a lipid of the lipid vesicle comprises a lipid selected from the group consisting of and (i) a double-stranded nucleic acid molecule and drug carrier comprising a mixture of a retinoid and a lipid, wherein the double-stranded nucleic acid molecule comprises the structure: 5' x -Z 3' (antisense strand) 3' Z'-(N') y -z" 5' (sense strand) wherein each of N and N' is a nucleotide which may be unmodified or modified, or an unconventional moiety; wherein each of x and (N') y is an oligonucleotide in which each consecutive N or N' is joined to the next N or N' by a covalent bond; wherein each of Z and Z' is independently present or absent, but if present independently includes 1-5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3'-terminus of the strand in which it is present; wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5'-terminus of (N') y; wherein each of x and y is independently an integer between 18 and 40; wherein the sequence of (N') y has complementary to the sequence of x; wherein x includes an antisense sequence to the mRNA coding sequence for human hsp47 exemplified by SEQ ID NO:1; and wherein the lipid comprises a lipid selected from the group consisting of and or wherein each of N and N' is a nucleotide which may be unmodified or modified, or an unconventional moiety; wherein each of x and (N') y is an oligonucleotide in which each consecutive N or N' is joined to the next N or N' by a covalent bond; wherein each of Z and Z' is independently present or absent, but if present independently includes 1-5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3'-terminus of the strand in which it is present; wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5'-terminus of (N') y; wherein each of x and y is independently an integer between 18 and 40; wherein the sequence of (N') y has complementary to the sequence of x; wherein x includes an antisense sequence to the mRNA coding sequence for human hsp47 exemplified by SEQ ID NO:1; and wherein the lipid comprises a lipid selected from the group consisting of and or (ii) a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and a drug carrier comprising a mixture of a lipid vesicle and a retinoid or a retinoid conjugate, wherein a lipid of the lipid vesicle comprises a lipid selected from the group consisting of and